PRTG Portage Biotech
- 0.240
- +0.003+1.35%
- 0.240
- 0.000-0.08%
Portage Biotech News
Retail Investing Startup Midas Raises $45 Million to Roll Out Crypto, Mutual Fund, and Savings Account Products
The $45 million fundraise was led by Portage and is one of Turkey's largest ever Series A rounds New capital will help Midas roll out a host of new product lines including crypto trading, mutual fund
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. Biora Therapeutics (NASDAQ:BIOR) share
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of The Travelers Companies, Inc. (NYSE:TRV) fell sharply during Wednesday's session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' e
Portage Biotech Explores Strategic Alternatives
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersPaxMedica (NASDAQ:PXMD) stock moved upwards by 104.2% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 million. Allarity Therapeutics (NASDAQ
Portage Biotech Halts Trial Enrollment, Seeks Strategic Options
Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives
WESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today
Press Release: Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) Shares
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares Company generated approximately $2.8M of non-dilutive funding to extend cash runway WESTPORT, Conn., March 26, 2024 (GL
12 Health Care Stocks Moving In Monday's After-Market Session
GainersStoke Therapeutics (NASDAQ:STOK) shares increased by 77.7% to $11.55 during Monday's after-market session. The company's market cap stands at $515.7 million. As per the news, the Q4 earnings re
Portage Biotech GAAP EPS of -$1.88 Misses by $1.61
Portage Biotech: Co Focused on Adenosine Platform Clinical Development >PRTG
Portage Biotech: Co Focused on Adenosine Platform Clinical Development >PRTG
Portage Biotech 3Q Loss/Shr $1.88 >PRTG
Portage Biotech 3Q Loss/Shr $1.88 >PRTG
Portage Biotech: Pausing Further Drug Development in the PORT-2 INKT Program >PRTG
Portage Biotech: Pausing Further Drug Development in the PORT-2 INKT Program >PRTG
Press Release: Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update Company focused on adenosine platform clinical development WESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSW
Modern Benefits Leader, Benepass, Secures $20M in Funding
With 100,000+ employees from top companies supported on its benefits platform, Benepass secures additional funding to rapidly scale distribution and accelerate product development NEW YORK , Jan. 31,
HC Wainwright & Co. Downgrades Portage Biotech to Neutral
HC Wainwright & Co. analyst Robert Burns downgrades Portage Biotech (NASDAQ:PRTG) from Buy to Neutral.
Analysts Offer Insights on Healthcare Companies: Harpoon Therapeutics (HARP), Portage Biotech Inc (PRTG) and Ambrx Biopharma (AMAM)
Opko Health, LifeMD Among Healthcare Movers
Portage Biotech to Cut Workforce as It Pauses A Drug Development Program, Evaluates Options
By Sabela Ojea Portage Biotech is evaluating strategic options and will reduce both its internal and contracted workforce as it pauses one of its programs. The clinical-stage immuno-oncology company
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersOmega Therapeutics (NASDAQ:OMGA) shares rose 110.6% to $5.75 during Thursday's pre-market session. The market value of their outstanding shares is at $317.0 million. Rapid Micro Biosystems (NAS
Analysis
Price Target
No Data
